RB1 and breast carcinoma: Importantly, preclinical studies with murine and human tumors and ex vivo human breast cancer tissue culture assays showed that antiprogestin responsiveness in breast cancer is determined by the PRA/PRB expression ratio, specifically, an inhibitory effect of the antiprogestin mifepristone is only obtained in tumors with higher levels of PRA than PRB [9, 10].